Active Genomes Expressed

Welcome. We’re AGED Diagnostics, and we’re disrupting the cancer diagnostics industry with our groundbreaking solutions and business ideas. Our technology has already been recognized by market leaders and our scalable business model is setting the trend for industry standards. Curious to find out more? Browse through our website, and get in touch if you would like to request a demo.



With our innovative and insightful technology, we strive to diagnose hepatocellular carcinoma (HCC or liver cancer) at an early stage to improve patient outcomes. Founded in 2017, our team of computational geneticists, virologists, hepatologists, engineers and entrepreneurs are working to bring AGED Diagnostics to the forefront of the hepatology industry.

Petri Dish
Embryonic Stem Cells


Hepatocellular Carcinoma (HCC or liver cancer) is the fastest growing cancer both worldwide and in the US. The current blood tests for HCC are less than 60% accurate and often fail to detect tumors at an early stage, and more accurate imaging alternatives are expensive. These challenges mean most patients are diagnosed at late stages, at which time the majority of patients will not live beyond a year.

HCC disproportionately affects individuals of African, Asian and Latin American origins with more aggressive phenotypes and decades earlier onset as compared to European counterparts. Current biomarkers do not account for differences between diversity groups. Although researchers have established that HCC presents with distinctive traits based on geographic origin, the molecular mechanisms that drive these discrepancies are still absent from being incorporated into standard of care for patients.



At AGED we are developing a non-invasive diagnostic test to detect liver cancer at an early stage. Liver cancer cells are targeted in the bloodstream and assessed through our core bioinformatics technology that identifies multiple factors that occur simultaneously in HCC.

Our methods will allow for assessment of the high degree of variability between how patients of different geographic origins develop HCC. By deploying a platform that assess multiple factors, these efforts will decrease liver cancer disparities by intentionally accounting differences between diversity groups. The outcome of these methods will provide hepatologists a non-invasive and affordable test to improve patient outcomes and decrease late stage HCC diagnosis.


Our Team

Rachel Zayas, Founder and CEO

Artemio Sison III, Computational Biologist

Dr. Bolni Marius Nagalo, Medical Oncology and Virology Specialist 

Greg Miller, Business Advisor

Dave McCarthy, Business Advisor

Daniel Kunitz, Business Advisor

Ariana Kuhnsman, Customer Engagement and Outreach Coordinator

Closeup of a Petri Dish


Washington DC


©2020 by AGED Diagnostics.